PRESS RELEASE

Released 07:00:06 14 December 2020

– AstraZeneca to acquire Alexion, accelerating the Company’s strategic and financial development
– Greater scientific presence in immunology by adding Alexion’s innovative complement-technology platforms and strong pipeline
– Dedicated rare disease unit to be headquartered in Boston
– Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care
– Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio
– Enhanced operating …

The post AstraZeneca snaps up Alexion Pharmaceuticals for $39bn appeared first on The Loadstar.

Source: The Loadstar